Results 101 to 110 of about 26,674 (238)
Efficacy and safety of abatacept in active primary Sjögren’s syndrome: results of a phase III, randomised, placebo-controlled trial
Annals of the Rheumatic Diseases, 2020 Objectives To evaluate efficacy and safety of abatacept in adults with active primary Sjögren’s syndrome (pSS) in a phase III, randomised, double-blind, placebo-controlled trial. Methods Eligible patients (moderate-to-severe pSS [2016 ACR/European League A. Baer, J. Gottenberg, E. S. St Clair, T. Sumida, T. Takeuchi, R. Seror, G. Foulks, M. Nys, S. Mukherjee, R. Wong, N. Ray, H. Bootsma +11 moresemanticscholar +1 more sourceAcyclovir‐Resistant Herpes Simplex Virus in Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant: A Case Series
Transplant Infectious Disease, EarlyView.This retrospective case series of acyclovir‐resistant HSV infection in pediatric patients undergoing allogeneic HSCT discusses the clinical course, associated complications, and treatment, including side effects. We propose the first algorithm for investigating and managing acyclovir‐resistant HSV infections in pediatric HSCT recipients, highlighting ...Jenna Nunn, Ahmed Ahmed, Srividhya Senthil, Oana Mirci‐Danicar, Denise Bonney, Claire Horgan, Omima Mustafa, Robert Wynn, Malcolm Guiver, Ramya Nataraj +9 morewiley +1 more sourceAbatacept increases T cell exhaustion in early RA individuals who carry HLA risk alleles
Frontiers in ImmunologyExhausted CD8 T cells (TEX) are associated with worse outcome in cancer yet better outcome in autoimmunity. Building on our past findings of increased TIGIT+KLRG1+ TEX with teplizumab therapy in type 1 diabetes (T1D), in the absence of treatment we found S. A. Long, V. Muir, Britta E. Jones, V. Wall, A. Ylescupidez, Anne M. Hocking, Stephan Pribitzer, Jerill Z Thorpe, Bryce Fuchs, A. Wiedeman, Megan Tatum, Katharina Lambert, H. Uchtenhagen, C. Speake, Bernard Ng, A. Heubeck, Troy R. Torgerson, A. Savage, Michael A Maldonado, Neelanjana Ray, Vadim Khaychuk, Jinqi Liu, Peter S. Linsley, J. Buckner +23 moresemanticscholar +1 more sourceThe clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation
, 2016 Background: Juvenile idiopathic arthritis (JIA) is characterised by joint pain, swelling and limitation of movement caused by inflammation. Subsequent joint damage can lead to disability and growth restriction.Abbvie, Albarouni, All Wales Medicines Strategy Group, All Wales Medicines Strategy Group, All Wales Medicines Strategy Group, All Wales Medicines Strategy Group, Angeles-Han, Arthritis Care, Arthritis Care, Arthritis Care, Arthritis Care, Arthritis Research UK, Baildam, Baildam, Barton, Baszis, Bechtold, Berard, Bertilsson, Briggs, Briggs, Bristol-Myers Squibb, British Society for Paediatric and Adolescent Rheumatology, British Society for Paediatric and Adolescent Rheumatology, Brodszky, Brunner, Brunner, Brunner, Brunner, Brunner, Bruns, Bucher, Burgos-Vargas, Burgos-Vargas, Burgos-Vargas, Burgos-Vargas, Burgos-Vargas, Burgos-Vargas, Canadian Agency for Drugs and Technologies in Health, Chang, Chen, Connock, Consolaro, Consolaro, Consolaro, Consolaro, Cordero-Coma, Costa, Cummins, Cummins, Curtis, Dakin, De Benedetti, De Benedetti, Department of Health, Dias, Diaz-Llopis, Donegan, Drummond, Duffy, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, Feeny, Foeldvari, Gani, Garcia-De-Vicuna, Geikowski, Giannini, Glenny, Haapasaari, Heiligenhaus, Hendry, Higgins, Higgins, Horizon Scanning Centre, Horneff, Horneff, Imagawa, Joint Formulary Committee, Kearsley-Fleet, Kearsley-Fleet, Kemper, Khan, Kingsbury, Klein, Kuhlthau, Lloyd Jones, Lovell, Lovell, Lovell, Lovell, Lovell, Lovell, Lovell, Lovell, Luca, Luca, Lundkvist, Magli, Malottki, Martin, McErlane, McErlane, Mills, Minden, Minden, Monthly Index of Medical Specialties, Moorthy, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Rheumatoid Arthritis Society, National Rheumatoid Arthritis Society (NRAS), NHS England Clinical Reference Group for Paediatric Medicine, NHS England Specialised Services Clinical Reference Group for Specialised Ophthalmology, Nikolakopoulou, Office for National Statistics, Otten, Otten, Packham, Paediatric Formulary Committee, Parsons, Pennington, Petty, Pfizer Ltd, Philips, Prakken, Prince, Prince, Prince, Prince, Ramanan, Ravelli, Ravelli, Reeves, Riemsma, Rigante, Roche, Ruperto, Ruperto, Ruperto, Ruperto, Ruperto, Ruperto, Ruperto, Simonini, Simonini, Simpson, Simpson, Simpson, Smith, Sonnenberg, Stagi, Stevenson, Thierry, Thomson, Thornton, Tong, Tse, Tynjala, Ungar, Ungar, Vidqvist, Wallace, Wallace, Wallace, Yagudina, Zannin, Zeng +171 morecore +1 more sourceThe development and assessment of biological treatments for children [PDF]
, 2014 The development of biological agents with specific immunological targets has revolutionized the treatment of a wide variety of paediatric diseases where traditional immunosuppressive agents have been partly ineffective or intolerable.Akobeng, Alexeeva, Alvarez, Andborn, Anink, Baldassano, Biester, Borker, Bout-Tabaku, Braun, Brennan, Brunner, Callen, Caorsi, Cezard, Choueiter, Choy, Cleary, Colombel, Crandall, De Benedetti, De Benedetti, De Cassan, Eberhard, Eleftheriou, Feagan, Fernandes, Fleischmann, Furie, Gasparetto, Gattorno, Gerloni, Giannini, Giannini, Hanauer, Hashkes, Horneff, Horneff, Horneff, Horneff, Horneff, Horneff, Hyams, Hyams, Hyams, Irvine, Jansson, Kahn, Kanakoudi-Tsakalidou, Kaneko, Kavanaugh, Kingsbury, Kok, Kuemmerle-Deschner, Kusuhara, Kutukculer, Lehman, Lehman, Lepore, Lequerre, Lin, Lofgren, Lovell, Lovell, Lovell, Lovell, Lovell, Lovell, Lowite, Luu, Mangge, Mohler, Munro, Myers, Navarra, Nigrovic, Otten, Paller, Papsdorf, Podolskaya, Prince, Prince, Quartier, Quartier, Quatrier, Robinson, Rosenbach, Rosh, Rothner, Ruemmele, Runner, Ruperto, Ruperto, Ruperto, Ruperto, Ruperto, Russell, Sakallioglu, Sandborn, Sandborn, Simard, Simonini, Southwood, Swart, Taylor, Toussi, Tynjala, Uperto, Vermeire, Viola, Wallace, Walters, Willems, Wyneski, Yokota, Yokota, Zannin, Zeft, Zulian +118 morecore +1 more sourceTreatment options for immune‐related adverse events associated with immune checkpoint inhibitors
British Journal of Pharmacology, Volume 183, Issue 6, Page 1271-1287, March 2026.Abstract
The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga +3 morewiley +1 more sourceUpdate on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs [PDF]
, 2016 A consensus paper concerning the interaction of anti-rheumatic drugs and reproduction was published in 2006, representing data collected during the year 2004 and 2005.Østensen, M., Lockshin, M., Doria, A., Valesini, G., Meroni, P., Gordon, C., Brucato, A., Tincani, A. +7 morecore +1 more source
